125 related articles for article (PubMed ID: 33209062)
1. PD-L1 Expression is Highly Associated with Tumor-Associated Macrophage Infiltration in Nasopharyngeal Carcinoma.
Deng R; Lu J; Liu X; Peng XH; Wang J; Li XP
Cancer Manag Res; 2020; 12():11585-11596. PubMed ID: 33209062
[TBL] [Abstract][Full Text] [Related]
2. Tumor-associated macrophages and PD-L1 in prostate cancer: a possible key to unlocking immunotherapy efficacy.
Wang J; Wu W; Yuan T; Wang L; Zang L; Liu Q; Wang L; Huo X; Huo B; Tang Y; Wang H; Zhao Z
Aging (Albany NY); 2024 Jan; 16(1):445-465. PubMed ID: 38189834
[TBL] [Abstract][Full Text] [Related]
3. Programmed Cell Death Ligand 1 Expression in CD163 + Tumor-associated Macrophages in Cancer Gland Rupture Microenvironment.
Baş Y; Yilmaz B; Acar SF; Karadağ İ
Appl Immunohistochem Mol Morphol; 2024 Apr; 32(4):176-182. PubMed ID: 38314768
[TBL] [Abstract][Full Text] [Related]
4. M2 subtype tumor associated macrophages (M2-TAMs) infiltration predicts poor response rate of immune checkpoint inhibitors treatment for prostate cancer.
JiaWei Z; ChunXia D; CunDong L; Yang L; JianKun Y; HaiFeng D; Cheng Y; ZhiPeng H; HongYi W; DeYing L; ZhiJian L; Xiao X; QiZhao Z; KangYi X; WenBing G; Ming X; JunHao Z; JiMing B; ShanChao Z; MingKun C
Ann Med; 2021 Dec; 53(1):730-740. PubMed ID: 34032524
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of CD68, CD163 and Folate receptor-β positive macrophages in hepatocellular carcinoma.
Minami K; Hiwatashi K; Ueno S; Sakoda M; Iino S; Okumura H; Hashiguchi M; Kawasaki Y; Kurahara H; Mataki Y; Maemura K; Shinchi H; Natsugoe S
Exp Ther Med; 2018 May; 15(5):4465-4476. PubMed ID: 29731831
[TBL] [Abstract][Full Text] [Related]
6. Breast Cancer Survival Outcomes and Tumor-Associated Macrophage Markers: A Systematic Review and Meta-Analysis.
Allison E; Edirimanne S; Matthews J; Fuller SJ
Oncol Ther; 2023 Mar; 11(1):27-48. PubMed ID: 36484945
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Number Density of Tumor-Associated Macrophages by Immunohistochemistry and Semiquantitative Scoring in Invasive Breast Cancer: An Indian Study.
Bhatia JK; Malik A; Chaudhary T; Gopal A; Boruah D; Singh B
J Microsc Ultrastruct; 2023; 11(4):214-219. PubMed ID: 38213652
[TBL] [Abstract][Full Text] [Related]
8. Predominance of M1 subtype among tumor-associated macrophages in phenotypically aggressive sporadic vestibular schwannoma.
Perry A; Graffeo CS; Carlstrom LP; Raghunathan A; Driscoll CLW; Neff BA; Carlson ML; Parney IF; Link MJ; Van Gompel JJ
J Neurosurg; 2019 Oct; 133(6):1637-1645. PubMed ID: 31585433
[TBL] [Abstract][Full Text] [Related]
9. A feed-forward loop based on aerobic glycolysis and TGF-β between tumor-associated macrophages and bladder cancer cells promoted malignant progression and immune escape.
Shen C; Liu J; Jiao W; Zhang X; Zhao X; Yang X; Wang Y
J Cancer Res Clin Oncol; 2023 Nov; 149(14):12867-12880. PubMed ID: 37462772
[TBL] [Abstract][Full Text] [Related]
10. TAMs and PD-1 Networking in Gastric Cancer: A Review of the Literature.
Yerolatsite M; Torounidou N; Gogadis A; Kapoulitsa F; Ntellas P; Lampri E; Tolia M; Batistatou A; Katsanos K; Mauri D
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201623
[TBL] [Abstract][Full Text] [Related]
11. The prognostic value of CD8
Jin Q; Jiang H; Yue N; Zhang L; Li C; Dong C; Zeng P; Yue L; Wu C
Leuk Lymphoma; 2024 Apr; 65(4):472-480. PubMed ID: 38198635
[TBL] [Abstract][Full Text] [Related]
12. Update on Radiotherapy Changes of Nasopharyngeal Carcinoma Tumor Microenvironment.
Zhu DQ; Su C; Li JJ; Li AW; Luv Y; Fan Q
World J Oncol; 2023 Oct; 14(5):350-357. PubMed ID: 37869238
[TBL] [Abstract][Full Text] [Related]
13. Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy.
Lu CS; Lin CW; Chang YH; Chen HY; Chung WC; Lai WY; Ho CC; Wang TH; Chen CY; Yeh CL; Wu S; Wang SP; Yang PC
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33243934
[TBL] [Abstract][Full Text] [Related]
14. Selected updates in molecular and genomic pathology of esophageal cancer.
Liu Y; Zhao L; Xue L; Hou Y
Ann N Y Acad Sci; 2020 Dec; 1482(1):225-235. PubMed ID: 33215736
[TBL] [Abstract][Full Text] [Related]
15. Targeting Tumor-Associated Macrophages to Increase the Efficacy of Immune Checkpoint Inhibitors: A Glimpse into Novel Therapeutic Approaches for Metastatic Melanoma.
Ceci C; Atzori MG; Lacal PM; Graziani G
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33212945
[TBL] [Abstract][Full Text] [Related]
16. Current status of cancer immunotherapy for gynecologic malignancies.
Nishio H; Iwata T; Aoki D
Jpn J Clin Oncol; 2021 Feb; 51(2):167-172. PubMed ID: 33244581
[TBL] [Abstract][Full Text] [Related]
17. Programmed Death Ligand 1 Is Overexpressed in Liver Macrophages in Chronic Liver Diseases, and Its Blockade Improves the Antibacterial Activity Against Infections.
Pose E; Coll M; Martínez-Sánchez C; Zeng Z; Surewaard BGJ; Català C; Velasco-de Andrés M; Lozano JJ; Ariño S; Fuster D; Niñerola-Bazán A; Graupera I; Muñoz É; Lozano F; Sancho-Bru P; Kubes P; Ginès P
Hepatology; 2021 Jul; 74(1):296-311. PubMed ID: 33219516
[TBL] [Abstract][Full Text] [Related]
18. Discovery Strategies to Maximize the Clinical Potential of T-Cell Engaging Antibodies for the Treatment of Solid Tumors.
Voynov V; Adam PJ; Nixon AE; Scheer JM
Antibodies (Basel); 2020 Nov; 9(4):. PubMed ID: 33217946
[TBL] [Abstract][Full Text] [Related]
19. Phenylboronic-acid-based nanocomplex as a feasible delivery platform of immune checkpoint inhibitor for potent cancer immunotherapy.
Lim J; Lee J; Jung S; Kim WJ
J Control Release; 2021 Feb; 330():1168-1177. PubMed ID: 33212120
[TBL] [Abstract][Full Text] [Related]
20. The optimal immune checkpoint inhibitors combined with chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis.
Yang Y; Luo H; Zheng XL; Ge H
Clin Transl Oncol; 2021 Jun; 23(6):1117-1127. PubMed ID: 33211281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
